CRL Charles River Laboratories International, Inc.
CRL Charles River Laboratories International, Inc.
Healthcare · Diagnostics & Research
Market read
Scan convergence 1 scan as of 2026-10-16 1 bull converging
POC $173.49 · VWAP $206.67 · +45.2% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, EVP + 4 others sold $14.3M, Aug 10–20
Coverage
1 watchlist
CRL Price Structure
Loading timeframes…
Peers
Every watchlist CRL belongs to, members best 30-day change first — CRL highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-06-27: revenue $1.00B, diluted EPS -$0.03, net income -$1M (SEC filing). Across the print the stock moved +13.4% (close before → first close after).
full note →Against street estimates
How CRL's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
CRL research tape
74 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to CRL.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries